chr2-166053049-C-A

Variant summary

Our verdict is Benign. The variant received -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBA1

The NM_001165963.4(SCN1A):​c.603-106G>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.703 in 1,421,714 control chromosomes in the GnomAD database, including 353,248 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.67 ( 34169 hom., cov: 33)
Exomes 𝑓: 0.71 ( 319079 hom. )

Consequence

SCN1A
NM_001165963.4 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 1.31

Publications

8 publications found
Variant links:
Genes affected
SCN1A (HGNC:10585): (sodium voltage-gated channel alpha subunit 1) Voltage-dependent sodium channels are heteromeric complexes that regulate sodium exchange between intracellular and extracellular spaces and are essential for the generation and propagation of action potentials in muscle cells and neurons. Each sodium channel is composed of a large pore-forming, glycosylated alpha subunit and two smaller beta subunits. This gene encodes a sodium channel alpha subunit, which has four homologous domains, each of which contains six transmembrane regions. Allelic variants of this gene are associated with generalized epilepsy with febrile seizures and epileptic encephalopathy. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5' untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript. [provided by RefSeq, Oct 2015]
SCN1A-AS1 (HGNC:54069): (SCN1A and SCN9A antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -18 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.24).
BP6
Variant 2-166053049-C-A is Benign according to our data. Variant chr2-166053049-C-A is described in ClinVar as Benign. ClinVar VariationId is 674938.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.869 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SCN1ANM_001165963.4 linkc.603-106G>T intron_variant Intron 7 of 28 ENST00000674923.1 NP_001159435.1 P35498-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SCN1AENST00000674923.1 linkc.603-106G>T intron_variant Intron 7 of 28 NM_001165963.4 ENSP00000501589.1 P35498-1
SCN1AENST00000303395.9 linkc.603-106G>T intron_variant Intron 6 of 27 5 ENSP00000303540.4 P35498-1
SCN1AENST00000375405.7 linkc.603-106G>T intron_variant Intron 4 of 25 5 ENSP00000364554.3 P35498-2
SCN1AENST00000409050.2 linkc.603-106G>T intron_variant Intron 6 of 27 5 ENSP00000386312.1 P35498-3

Frequencies

GnomAD3 genomes
AF:
0.667
AC:
101163
AN:
151782
Hom.:
34141
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.574
Gnomad AMI
AF:
0.644
Gnomad AMR
AF:
0.717
Gnomad ASJ
AF:
0.602
Gnomad EAS
AF:
0.891
Gnomad SAS
AF:
0.708
Gnomad FIN
AF:
0.756
Gnomad MID
AF:
0.513
Gnomad NFE
AF:
0.683
Gnomad OTH
AF:
0.637
GnomAD4 exome
AF:
0.707
AC:
897554
AN:
1269814
Hom.:
319079
Cov.:
23
AF XY:
0.703
AC XY:
450921
AN XY:
641396
show subpopulations
African (AFR)
AF:
0.584
AC:
17127
AN:
29326
American (AMR)
AF:
0.790
AC:
34822
AN:
44094
Ashkenazi Jewish (ASJ)
AF:
0.605
AC:
14981
AN:
24774
East Asian (EAS)
AF:
0.896
AC:
34791
AN:
38826
South Asian (SAS)
AF:
0.686
AC:
56333
AN:
82106
European-Finnish (FIN)
AF:
0.749
AC:
39769
AN:
53128
Middle Eastern (MID)
AF:
0.502
AC:
2694
AN:
5370
European-Non Finnish (NFE)
AF:
0.703
AC:
660059
AN:
938352
Other (OTH)
AF:
0.687
AC:
36978
AN:
53838
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.539
Heterozygous variant carriers
0
12933
25866
38798
51731
64664
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
15676
31352
47028
62704
78380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.666
AC:
101235
AN:
151900
Hom.:
34169
Cov.:
33
AF XY:
0.672
AC XY:
49924
AN XY:
74256
show subpopulations
African (AFR)
AF:
0.574
AC:
23764
AN:
41426
American (AMR)
AF:
0.718
AC:
10926
AN:
15216
Ashkenazi Jewish (ASJ)
AF:
0.602
AC:
2088
AN:
3466
East Asian (EAS)
AF:
0.891
AC:
4599
AN:
5162
South Asian (SAS)
AF:
0.708
AC:
3417
AN:
4826
European-Finnish (FIN)
AF:
0.756
AC:
8009
AN:
10594
Middle Eastern (MID)
AF:
0.507
AC:
149
AN:
294
European-Non Finnish (NFE)
AF:
0.683
AC:
46347
AN:
67896
Other (OTH)
AF:
0.640
AC:
1350
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
1744
3488
5233
6977
8721
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
812
1624
2436
3248
4060
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.666
Hom.:
12316
Bravo
AF:
0.659
Asia WGS
AF:
0.773
AC:
2688
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jun 14, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

not specified Benign:1
Jul 15, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 81% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 75. Only high quality variants are reported. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.24
CADD
Benign
17
DANN
Benign
0.79
PhyloP100
1.3
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3812719; hg19: chr2-166909559; API